Objectives: The aim of this study was to determine if fluorodeoxyglucose positron emission tomography (FDG-PET) uptake can be used in pretreatment assessment as an additional prognostic factor for outcome in head and neck cancer patients receiving radiotherapy by helical tomotherapy (Hi-Art Tomotherapy®) +/- chemotherapy. Methods: Between June 2005 and March 2008, 58 patients with a biopsy proven head and neck cancer (HNC) were treated at the Universitair Ziekenhuis Brussel (UZ Brussel). All patients underwent a baseline FDG-PET before treatment. The maximum Standardized Uptake Value (SUVmax) was measured within the lesions. Median SUVmax was used as a cutoff to categorize patients into high and low SUVmax groups. Results: Median SUVmax = 7.92. Median SUVmax for patients who died was significantly higher than living patients (9.16 vs. 7.32, respectively, p= 0.037). 3-years Overall survival (OS) was 80% vs. 54% (p = 0.009) and disease free survival (DFS) was 83% vs. 41% (p = 0.018) for low and high SUVmax groups, respectively. Multivariate analysis also confirmed these observations. Conclusion: PET-FDG scan before treatment is a good predictor of outcome in HNC patients. It may helps in early identification of patients with poor prognosis for perhaps other therapeutic approaches.
Farrag, A. (2010). Fluorodeoxyglucose Positron Emission Tomography as Predictive Factor for the Outcome of Head and Neck Cancer Patients. Egyptian Journal Nuclear Medicine, 3(3), 18-26. doi: 10.21608/egyjnm.2010.5497
MLA
Ashraf Farrag. "Fluorodeoxyglucose Positron Emission Tomography as Predictive Factor for the Outcome of Head and Neck Cancer Patients", Egyptian Journal Nuclear Medicine, 3, 3, 2010, 18-26. doi: 10.21608/egyjnm.2010.5497
HARVARD
Farrag, A. (2010). 'Fluorodeoxyglucose Positron Emission Tomography as Predictive Factor for the Outcome of Head and Neck Cancer Patients', Egyptian Journal Nuclear Medicine, 3(3), pp. 18-26. doi: 10.21608/egyjnm.2010.5497
VANCOUVER
Farrag, A. Fluorodeoxyglucose Positron Emission Tomography as Predictive Factor for the Outcome of Head and Neck Cancer Patients. Egyptian Journal Nuclear Medicine, 2010; 3(3): 18-26. doi: 10.21608/egyjnm.2010.5497